Shlomo Meislin Harnas is an accomplished healthcare and life science commercial strategist with extensive experience in consulting and industry. He has worked with biopharma and medtech companies, startups, and investors to evaluate, develop, and commercialize new therapies and products. With a particular focus on commercial strategy and business planning, opportunity assessments, acquisition/licensing support, new product/portfolio development, forecasting and analytics, and market entry strategy, Shlomo is a sought-after expert in the US, EU, and emerging markets. His areas of expertise include orphan/rare disease and specialty therapeutics, making him an invaluable asset to any company looking to innovate in these areas.

Shlomo's education includes an S.M. in Biology from the Massachusetts Institute of Technology and an M.S. in Biochemistry, B.S. in Biology, and B.A. in Mathematics from Brandeis University. He is currently the Managing Director at Akrolyth Consulting & Analytics, having previously served as an advisor and investor at various companies and a Strategy Advisor at Articulate Labs.

Overall, Shlomo is known for his versatility, depth of insight, and ability to navigate complexity, providing structure and clarity to even the most challenging questions. His breadth of knowledge across a variety of therapeutic areas and his deep understanding of the commercial landscape make him a valuable asset to any team.